Genta Incorporated Receives $2.8 Million in Non-Dilutive Proceeds from Tax Sale and Designation by European Medicines Evaluation Agency as a Small Business Entity

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETA) announced that it has received $2.8 million in non-dilutive cash proceeds from the sale of net operating tax losses and research tax credits generated in prior tax years as part of the Technology Business Tax Certificate Program sponsored by the New Jersey Economic Development Authority (NJEDA), pursuant to the rules, regulations and stipulations set forth by the program. This program, which focuses on biotechnology and other research-based companies, is designed to attract and retain knowledge-intensive businesses that will enhance the State’s strategic and competitive interests in these areas.
MORE ON THIS TOPIC